Search

everythinglearnresearchcommunity

for

Search:↓

An 18-year-old male experiencing hair loss since 2023 is using minoxidil, microneedling, and topical finasteride. He is considering switching to oral finasteride for potentially better results.

A user discussed the "Rootique Duo," a device that turns minoxidil into mist for scalp application, but others suggested cheaper alternatives like an AliExpress applicator. Some users prefer traditional methods like droppers or spray nozzles, especially for longer hair.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.

The user is experiencing hair thinning and loss at the temples, likely due to androgenetic alopecia. Suggested treatments include finasteride and minoxidil to slow hair loss and promote regrowth, with buzzing hair short as a styling option.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. User asks how much alfatradiol lowers DHT levels.

The conversation discusses the use of RU58841 for hair loss, with concerns about its legality in Germany and potential legal consequences. Alternatives like finasteride and dutasteride are mentioned, with some users questioning the effectiveness and safety of RU58841.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

A user is using a topical treatment called Formula 82f, which contains finasteride, minoxidil, and a steroid, along with Ketoconazole shampoo for hair loss. They are considering whether to switch to oral medication for better results.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The user is experiencing hair regrowth using a combination of oral finasteride, a minoxidil/finasteride topical spray, and dermarolling. They plan to continue this regimen and may consider adding dutasteride if needed.

The conversation is about someone experiencing hair thinning at the temples and seeking alternative treatments to Minoxidil due to side effects. They are inquiring about the effectiveness of peppermint oil and dermarolling for hair growth.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.

Piroctone olamine may be more effective and gentler than ketoconazole for dandruff and itchiness. Users report better results with piroctone olamine, but it is less available in the US.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.

A user shared progress pictures showing improvement from NW 6 to NW 2 after four months of treatment. They are considering using exosomes to further reverse hair miniaturization.

Topical minoxidil with retinoic acid is effective but causes scalp irritation, leading the user to consider switching to 2.5mg oral minoxidil. Oral minoxidil may cause body hair growth and heart-related side effects, so it's advised to use it under medical guidance.

The user is considering starting oral Minoxidil at 2.5 mg to regrow hair, despite already using Finasteride, and is concerned about the cost, side effects, and prescription difficulties. They question if the potential hair gains would be noticeable given their current hairstyle.

The user experienced noticeable hair regrowth after using finasteride for 2 years, oral minoxidil for 1 year, and recently starting dermarolling. The right temple shows significant improvement, while the left remains similar.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The user experienced severe scalp itching and hair loss while on dutasteride, which they linked to caffeine and masturbation. They plan to cut out both to see if their hair density improves.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

The post and conversation are about a user claiming to be 137 years old with a full head of hair. Specific treatments mentioned include dutasteride, RU58841, and minoxidil.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

RU58841 should be applied directly to the scalp, ideally once a day, a few hours before bed. Some users experienced side effects like shedding and systemic issues when using RU58841 and Minoxidil together, while others reported no side effects when using RU58841 alone.

A 15-year-old is seeking advice on preventing hair loss, identified as Norwood level 2, and wants tips for growing long hair. They have consulted a trichologist who recommended specific shampoos.